TheraRadar
← Back
Data updated: Jun 28, 2026

Sanofi

SNY Big Pharma
MetabolicOncologyInfectious Disease Execution: Good

French pharma with diverse portfolio spanning vaccines (Fluzone), immunology (Dupixent), and rare diseases (Fabrazyme). Growing focus on immunology.

$46.1B
Revenue (2024)
$130.0B
Market Cap
-
Trials
2
New Drugs (2yr)
Modality:
20 Small Molecules 35 Biologics

FDA Novel Drug Designations

(2017-2025)
7 Novel 4 First-in-Class 6 Orphan 2 Breakthrough 3 Priority Review 4 Fast Track
See 7 novel approvals →
2025 QFITLIA (FITUSIRAN SODIUM) First-in-Class · Orphan · Fast Track
2025 WAYRILZ (RILZABRUTINIB) First-in-Class · Orphan · Fast Track
2022 XENPOZYME (OLIPUDASE ALFA-RPCP) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
2021 FEXINIDAZOLE Orphan · Priority Review
2021 NEXVIAZYME (AVALGLUCOSIDASE ALFA-NGPT) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
2020 SARCLISA (ISATUXIMAB-IRFC) Orphan
2017 KEVZARA (SARILUMAB)

Sanofi at a Glance

  • Fast trial execution (19 months median completion)

Sanofi's Key Drugs

Sanofi's core commercial portfolio centers on ALTUVIIIO, KEVZARA, NEXVIAZYME, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.

ALTUVIIIO
Approved 2023
KEVZARA
Immunology

Rheumatoid Arthritis

IL-6R Approved 2017
NEXVIAZYME
Rare Disease

Pompe Disease

Acid α-glucosidase Approved 2021
SARCLISA
Oncology

Multiple Myeloma

CD38 Approved 2020
Alprolix
Approved 2014

Sanofi's Recent FDA Approvals

Sanofi secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

WAYRILZ NDA
2025-08-29
rilzabrutinib
Immune Thrombocytopenia
QFITLIA NDA
2025-03-28
fitusiran sodium
Hemophilia A

Sanofi's Therapeutic Areas

Sanofi's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 35 biologic and 20 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 30%
7 drugs Phase 3: 70 Phase 2: 12 Phase 1: 100
Oncology 27%
9 drugs Phase 3: 34 Phase 2: 57 Phase 1: 101
Infectious Disease 17%
1 drugs Phase 3: 44 Phase 2: 24 Phase 1: 26
Immunology 14%
2 drugs Phase 3: 23 Phase 2: 37 Phase 1: 28
Cardiovascular 11%
4 drugs Phase 3: 27 Phase 2: 10 Phase 1: 15

Sanofi Pipeline Snapshot

Sanofi has 608 active clinical programs from ClinicalTrials.gov — 198 Phase 3, 140 Phase 2 and 270 Phase 1.

198
Phase 3
140
Phase 2
270
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ALTUVIIIO leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 224/312 completed
  • • Speed: 19 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges